ASP 5878Alternative Names: ASP5878
Latest Information Update: 06 Apr 2016
At a glance
- Originator Astellas Pharma
- Class Antineoplastics
- Mechanism of Action Fibroblast growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 21 Oct 2015 Phase-I development for Solid tumours is ongoing in Japan (NCT02038673)
- 01 Nov 2013 Phase-I clinical trials in Solid tumours in Japan (PO)